Change of liquidity contract for CROSSJECT

CROSSJECT, a company specializing in the development of products for medical emergencies, announced the termination of its liquidity agreement with All Invest Securities. As of June 30, 2025, the liquidity account included 59,366 shares and €65,132.38. As of July 1, 2025, a new agreement was established with Rothschild Martin Maurel for a one-year period, automatically renewable.

This agreement aims to support CROSSJECT's actions on Euronext Paris, thus promoting liquidity and regularity of transactions. The same financial resources are allocated for this new agreement. The suspension of the agreement may occur under certain conditions, including those provided for in AMF Decision No. 2021-01.